How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

37,011 results for

Breast Cancer Diagnosis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Somatic tumour gene testing for the diagnosis of renal cell carcinoma, hydatidiform moles, granulosa cell ovarian tumour, salivary gland tumours, and secretory carcinoma of the breast

or mammary analogue secretory carcinoma (MASC) of salivary glands. Fee: $454 each OR In the assessment of malignant salivary gland tumours, identification of: • MALM2 gene status for the diagnosis of mucoepidermoid carcinoma AND/OR • ETV6-NTRK3 gene status for the diagnosis of analogue secretory carcinoma AND/OR • EWSR1 gene status for the diagnosis of hyalinising clear cell carcinoma. Fee: $454 (for each) OR Identification of TFE3 or TFEB gene rearrangement in the assessment of renal cell carcinoma. Fee (...) Somatic tumour gene testing for the diagnosis of renal cell carcinoma, hydatidiform moles, granulosa cell ovarian tumour, salivary gland tumours, and secretory carcinoma of the breast 1 Public Summary Document Application No. 1528 – Hydatidiform mole testing Applicant: The Royal College of Pathologists of Australasia (RCPA) Date of MSAC consideration: MSAC 77 th Meeting, 28-29 November 2019 MSAC 76 th Meeting, 1-2 August 2019 Context for decision: MSAC makes its advice in accordance with its

2020 Medical Services Advisory Committee

2. Elevated risk of radiotherapy-associated second malignant neoplasms in young African American women survivors of stage I-IIIA breast cancer. (Abstract)

Elevated risk of radiotherapy-associated second malignant neoplasms in young African American women survivors of stage I-IIIA breast cancer. To estimate the impact of radiotherapy (RT) on non-breast second malignant neoplasms (SMNs) in young women survivors of stage I-IIIA breast cancer.Women aged 20-44 years diagnosed with stage I-IIIA breast cancer (1988-2008) were identified in Surveillance, Epidemiology, and End Results (SEER) 9 registries. Bootstrapping approach and competing risk (...) proportional hazards models were used to evaluate the effect of RT on non-breast SMN risk. The analysis was repeated in racial subgroups. Radio-tolerance score (RTS) analysis of normal airway epithelium was performed using Gene Expression Omnibus (GEO) datasets.Within records of 30,003 women with primary breast cancer, 20,516 eligible patients were identified (including 2,183 African Americans [AAs] and 16,009 Caucasians). The 25-year cumulative incidences of SMN were 5.2% and 3.6% (RT vs. no-RT) for AAs

2019 Biology and Physics

3. Skin Diseases of the Breast and Nipple Part I: Benign and Malignant Tumors. (Abstract)

Skin Diseases of the Breast and Nipple Part I: Benign and Malignant Tumors. Evaluation and management of dermatologic diseases of the breast and nipple requires an understanding of the unique anatomy of the breast and nipple as well as an awareness of the significant emotional, cultural, and sexual considerations that may come into play when treating this anatomic area. Part I of this 2 Part CME Series reviews breast anatomy, congenital breast anomalies, and benign and malignant breast tumors (...) . Specifically, an emphasis is placed on inflammatory breast cancer and breast cancer with non-inflammatory skin involvement as well as on cutaneous metastases to the breast and from breast cancer. Familiarity of the dermatologist with the cutaneous manifestations of breast cancer will facilitate the diagnosis of breast malignancy and assist with staging, prognostication, and evaluation for recurrence. This article also discusses genodermatoses that predispose to breast pathology and provides imaging

2018 Journal of American Academy of Dermatology

4. An Unusual Salivary Gland Tumor Mimicking Papillary Thyroid Carcinoma: Mammary Analog Secretory Carcinoma Full Text available with Trip Pro

An Unusual Salivary Gland Tumor Mimicking Papillary Thyroid Carcinoma: Mammary Analog Secretory Carcinoma Thyroid tumors usually present as masses in the thyroid gland. While the majority of these tumors represent neoplasms of thyroid tissues, mainly of follicular epithelial cell differentiation, the differential diagnosis includes other lesions, such as C cell neoplasms (medullary thyroid carcinoma), intrathyroidal parathyroid, or thymic tumors, soft tissue tumors, and hematologic neoplasms (...) as well as metastatic malignancies. Rare tumors are of salivary gland types. This case illustrates an unusual tumor of salivary gland type, an intrathyroidal mammary analog secretory carcinoma (MASC). The pathogenesis, diagnostic pitfalls, and therapeutic implications of this unusual tumor are discussed.

2018 Frontiers in endocrinology

5. Photoacoustic Imaging in Diagnosing Changes in Tumors in Participants With Breast Cancer, Sarcoma, Skin Cancer, or Soft Tissue Malignancy and Healthy Volunteers

in tumors after chemotherapy or radiation treatment. Condition or disease Intervention/treatment Phase Breast Carcinoma Healthy Subject Malignant Soft Tissue Neoplasm Sarcoma Skin Carcinoma Procedure: Photoacoustic Imaging Not Applicable Detailed Description: PRIMARY OBJECTIVES: I. To define the feasibility of the current photoacoustic imaging (PAI) technology in various groups of human subjects. SECONDARY OBJECTIVES: I. To define the utility of the current PAI on various groups of human subjects. II (...) Photoacoustic Imaging in Diagnosing Changes in Tumors in Participants With Breast Cancer, Sarcoma, Skin Cancer, or Soft Tissue Malignancy and Healthy Volunteers Photoacoustic Imaging in Diagnosing Changes in Tumors in Participants With Breast Cancer, Sarcoma, Skin Cancer, or Soft Tissue Malignancy and Healthy Volunteers - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study

2018 Clinical Trials

6. Transcriptome Signatures of Canine Mammary Gland Tumors and Its Comparison to Human Breast Cancers Full Text available with Trip Pro

Transcriptome Signatures of Canine Mammary Gland Tumors and Its Comparison to Human Breast Cancers Breast cancer (BC)/mammary gland carcinoma (MGC) is the most frequently diagnosed and leading cause of cancer-related mortality in both women and canines. To better understand both canine MGC and human BC-specific genes, we sequenced RNAs obtained from eight pairs of carcinomas and adjacent normal tissues in dogs. By comprehensive transcriptome analysis, 351 differentially expressed genes (DEGs (...) ) were identified in overall canine MGCs. Based on the DEGs, comparative analysis revealed correlation existing among the three histological subtypes of canine MGC (ductal, simple, and complex) and four molecular subtypes of human BC (HER2+, ER+, ER&HER2+, and TNBC). Eight DEGs shared by all three subtypes of canine MGCs had been previously reported as cancer-associated genes in human studies. Gene ontology and pathway analyses using the identified DEGs revealed that the biological processes

2018 Cancers

7. AIM Clinical Appropriateness Guidelines for Molecular Testing of Solid and Hematologic Tumors and Malignancies

or Thrombocytosis 17 Primary Myelofibrosis 18 Genetic Testing for Hematologic Malignancy 18 Minimal Residual Disease (MRD) Genetic Testing 18 Solid Tumor Testing 19 NTRK Fusion Testing 19 PIK3CA Testing 20 Breast Cancer 20 Lung Cancer 22 Cell-Free Tumor Testing 23 Cancer of Unknown Primary/Occult Neoplasm 23 Pancreatic Cancer 24 Prostate Cancer 25 Thyroid Cancer 26 Cancer Screening 26 Indeterminate Thyroid Nodules 26 Colorectal Cancer Screening 28 Professional Society Guidelines 29 PROPRIETARY Guidelines (...) nephroma, secretory breast cancer, mammary secretory carcinoma of the salivary gland, spitzoid melanoma, metastatic papillary thyroid cancer, analog pediatric high-grade glioma, or GIST when no KIT/PDGFRA/RAS pathogenic or likely pathogenic (P/LP variant) is identified) ? In solid tumors of smooth muscle, testes, or neural tissue when all of the following criteria are met: - Standard of care treatment options have been exhausted - Cancer continues to progress - Tumor type has been shown to respond

2020 AIM Specialty Health

8. Neratinib (Nerlynx) - Breast cancer, breast neoplasms

disease-free survival DFS-DCIS disease-free survival including ductal carcinoma in situ ECG electrocardiogram ECOG Eastern Cooperative Oncology Group EGFR epidermal growth factor receptor EQ-5D EuroQol 5-Dimension Questionnaire ER estrogen receptor ERBB erythroblastic leukemia viral oncogene homolog; also termed HER ExteNET Extended Adjuvant Treatment of Breast Cancer with Neratinib FACT-B Functional Assessment of Cancer Therapy-Breast FMO flavin-containing monooxygenase GI gastrointestinal HER human (...) -stage HER2-overexpressed/amplified breast cancer at high risk of recurrence (node positive and within 1 year of completion of prior adjuvant trastuzumab based therapy). 2.1.2. Epidemiology, screening tools/prevention Breast cancer is the most frequently diagnosed malignancy in women and the leading cause of cancer mortality in women worldwide. In 2012, the estimated age-adjusted annual incidence of breast cancer Assessment report EMA/CHMP/525204/2018 Page 9/169 in 40 European countries was 94.2/100

2018 European Medicines Agency - EPARs

9. AIM Clinical Appropriateness Guidelines for Molecular Testing of Solid and Hematologic Tumors and Malignancies

criteria below for: • Myeloproliferative neoplasmsBreast Cancer • Cell-Free Tumor Testing • Cancer of Unknown Primary/Occult Neoplasm • Prostate Cancer (confirmed, not screening) • Thyroid Cancer and Indeterminate Thyroid Nodules • Colorectal Cancer Screening Polycythemia Vera JAK2 mutation testing is medically necessary for the diagnosis of polycythemia vera when both of the following conditions are met: • Genetic testing impacts medical management • ONE of the following criteria are met (...) Use Criteria 3 National Comprehensive Cancer Network® (NCCN®) Criteria* 4 Polycythemia Vera 5 Essential Thrombocythemia or Thrombocytosis 5 Primary Myelofibrosis 5 Breast Cancer 6 Cancer of Unknown Primary/Occult Neoplasm 7 Prostate Cancer 7 Screening 7 Confirmed Malignancy 7 Thyroid Cancer 7 Confirmed or Highly-Suspected Thyroid Cancer 7 Cytologically Indeterminate Thyroid Nodule 7 Colorectal Cancer Screening 8 CPT Codes 8 Background 12 Myeloproliferative Disorders 12 Polycythemia Vera 12

2019 AIM Specialty Health

10. Radiotherapy with apatinib for recurrence of malignant phyllodes tumor of the breast: A case report. Full Text available with Trip Pro

treatment, the tumor recurred in the chest wall scar.The histopathologic diagnoses was right breast malignant phyllodes tumor with chondrosarcomas and osteosarcomas in some areas.The patient was first treated with surgery. Malignant phyllodes tumor recurred in the chest wall two months after surgery and was treated with radiotherapy and apatinib.With surgery, radiotherapy and apatinib treatment, the patient still died within several months.Apatinib and radiotherapy failed to obtain good therapeutic (...) Radiotherapy with apatinib for recurrence of malignant phyllodes tumor of the breast: A case report. Malignant phyllodes tumors of the breast are rare, and there are currently no guidelines and a large number of clinical trials to guide the treatment of recurrence tumor. Here we reported a case of radiotherapy with apatinib for the treatment of recurrent malignant phyllodes tumor of the breast.A 58-year-old patient with massive breast mass was admitted to our hospital. Two months after surgical

2020 Medicine

11. Trastuzumab (Kanjinti) Breast Neoplasms, Stomach Neoplasms

or early breast cancer whose tumours have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay (see sections 4.4 and 5.1). Assessment report EMA/CHMP/261937/2018 Page 7/71 Metastatic gastric cancer Kanjinti in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer (...) a shortened disease-free survival compared to patients whose tumours do not overexpress HER2. HER2 overexpression was found in a number of disease states, including metastatic breast cancers, early breast cancer and metastatic gastric cancer (MGC). The extracellular domain of the receptor (ECD) can be shed into the blood stream and measured in serum samples (see Herceptin SmPC section 5.1). Trastuzumab binds with high affinity and specificity to sub-domain IV, a juxta membrane region of HER2’s

2018 European Medicines Agency - EPARs

12. Ultrasonography methods for predicting malignancy in canine mammary tumors. Full Text available with Trip Pro

Ultrasonography methods for predicting malignancy in canine mammary tumors. The aim of this study was to evaluate and compare the efficacy of B-mode, Doppler, contrast-enhanced ultrasonography (CEUS), and Acoustic Radiation Force Impulse (ARFI) elastography in predicting malignancy in canine mammary masses. This was a prospective cohort study from 2014 to 2016, which included 153 bitches with one or more mammary masses. A total of 300 masses were evaluated by ultrasonography (B-mode, Doppler (...) using histopathological classification as reference, to assess and compare diagnostic performance of each technique. Out of 300 mammary masses evaluated 246 were classified as malignant and 54 as benign. B-mode measurements showed sensitivity 67.9%, and specificity 67.6% as malignancy predictors on canine mammary masses; Doppler indexes systolic (>21.2 m/s) and diastolic velocity (>4.8 m/s) sensitivity 79.2% and specificity 70.8%; CEUS wash-out time (<80.5 s) sensitivity 80.2% and specificity 16.7

2017 PLoS ONE

13. The investigation of transcriptional repression mediated by ZEB2 in canine invasive micropapillary carcinoma in mammary gland. Full Text available with Trip Pro

The investigation of transcriptional repression mediated by ZEB2 in canine invasive micropapillary carcinoma in mammary gland. The E-cadherin loss has frequently been associated with transcriptional repression mediated by transcription factors, such as the Zinc Finger E-Box Binding Homeobox-2 (ZEB2). Invasive micropapillary carcinomas (IMPCs) of the breast are aggressive neoplasms frequently related to lymph node metastasis and poor overall survival. In the canine mammary gland, IMPCs has just (...) been reported and, based on its behavioral similarity with the human IMPCs, appears to be a good spontaneous model to this human entity. This study aimed to evaluate the relationship between E-cadherin and ZEB2 in a spontaneous canine model of invasive micropapillary carcinoma of the mammary gland. The correlation among gene expression (ZEB2 and CDH1) and clinicopathological findings was also explored. Nineteen cases of IMPC of the canine mammary gland were obtained, protein and mRNA expression

2019 PLoS ONE

14. Challenging tumour immunological techniques that help to track cancer stem cells in malignant melanomas and other solid tumours Full Text available with Trip Pro

tissue sections were set up and standardized.We showed strong tumour-associated disialylated glycosphingolipid expression levels on various cancer cells using scFv antibody fragments, generated previously by uniquely invasive breast carcinoma TIL-B phage display library technology.We report herein a novel strategy to obtain antibody fragments of human origin that recognise tumour-associated ganglioside antigens. Our investigations have the power to detect privileged molecules in cancer progression (...) Challenging tumour immunological techniques that help to track cancer stem cells in malignant melanomas and other solid tumours The arsenal of questions and answers about the minor cancer initiating cancer stem cell (CSC) population put responsible for cancer invasiveness and metastases, has left with an unsolved puzzle. Specific aims of a complex project were partly focused on revealing new biomarkers of cancer. We designed and set up novel techniques to facilitate the detection of cancerous

2018 Contemporary Oncology

15. Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy Full Text available with Trip Pro

Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy Purpose Childhood cancer survivors (CCSs) are at increased risk for subsequent malignant neoplasms (SMNs). We evaluated the long-term risk of SMNs in a well-characterized cohort of 5-year CCSs, with a particular focus on individual chemotherapeutic agents and solid cancer risk. Methods The Dutch Childhood Cancer Oncology Group-Long-Term Effects After (...) Childhood Cancer cohort includes 6,165 5-year CCSs diagnosed between 1963 and 2001 in the Netherlands. SMNs were identified by linkages with the Netherlands Cancer Registry, the Dutch Pathology Registry, and medical chart review. We calculated standardized incidence ratios, excess absolute risks, and cumulative incidences. Multivariable Cox proportional hazard regression analyses were used to evaluate treatment-associated risks for breast cancer, sarcoma, and all solid cancers. Results After a median

2017 EvidenceUpdates

16. Strain histograms are equal to strain ratios in predicting malignancy in breast tumours. Full Text available with Trip Pro

Strain histograms are equal to strain ratios in predicting malignancy in breast tumours. To assess whether strain histograms are equal to strain ratios in predicting breast tumour malignancy and to see if either could be used to upgrade Breast Imaging Reporting and Data System (BI-RADS) 3 tumours for immediate biopsy.Ninety-nine breast tumours were examined using B-mode BI-RADS scorings and strain elastography. Strain histograms and ratios were assessed, and areas- under-the-receiver-operating (...) -characteristic-curve (AUROC) for each method calculated. In BI-RADS 3 tumours cut-offs for strain histogram and ratio values were calculated to see if some tumours could be upgraded for immediate biopsy. Linear regression was performed to evaluate the effect of tumour depth and size, and breast density on strain elastography.Forty-four of 99 (44.4%) tumours were malignant. AUROC of BI-RADS, strain histograms and strain ratios were 0.949, 0.830 and 0.794 respectively. There was no significant difference

2017 PLoS ONE

17. The clinical application of tumor markers in the screening of malignancies and interstitial lung disease of dermatomyositis/polymyositis patients: A retrospective study Full Text available with Trip Pro

detected: breast ductal carcinoma (n = 4), bladder transitional cell carcinoma (n = 2), lung adenocarcinoma (n = 2), cervical intraepithelial neoplasia 3 and papillary squamous cell carcinoma (n = 2), colorectal (colon and rectal adenocarcinoma) (n = 2), uterine adenocarcinoma (n = 1), nasopharyngeal carcinoma (n = 1) and hematological malignancy (myelodysplastic with excess blast cells) (n = 1). Among the patients with malignancies, 13 (86.7%) had dermatomyositis, 2 (13.3%) polymyositis and 3 (20 (...) %) interstitial lung disease. The mean duration from dermatomyositis/polymyositis diagnosis to the occurrence of malignancies was 6.05 ± 5.69 years. There was no significant association of raised tumor markers with the occurrence of malignancies (p > 0.085), while a significant association was observed between the elevated levels of carbohydrate antigen 15-3 and the presence of interstitial lung disease (p = 0.006).Tumor markers were not useful in malignancy screening or dermatomyositis/polymyositis patients

2018 SAGE open medicine

18. Management of Female Malignant Ovarian Germ Cell Tumours

Management of Female Malignant Ovarian Germ Cell Tumours Management of Female Malignant Ovarian Germ Cell T umours Scientific Impact Paper No. 52 November 2016Management of Female Malignant Ovarian Germ Cell Tumours 1. Background Female malignant ovarian germ cell tumours (MOGCTs) are rare, but early diagnosis and multiagent chemotherapy are associated with high cure rates of 85.6% (range 81.2–90.0%). 1 While sharing many similarities with male germ cell tumours (GCTs), a group of cancers 20 (...) treatment Women who have residual masses at completion of chemotherapy should be offered resection even if the tumour markers are normal. 41 This is to exclude residual disease or any residual mature teratoma which can progress as mature teratoma growing syndrome in up to 30% of cases, and more rarely, over time, undergo malignant transformation into an incurable tumour type, such as squamous carcinoma. Early recognition of this syndrome is essential as it offers hope for curative resection and avoids

2016 Royal College of Obstetricians and Gynaecologists

19. The Rare Benign Lesion That Mimics a Malignant Tumor in Breast Parenchyma: Nodular Fasciitis of the Breast Full Text available with Trip Pro

in a storiform pattern. Immunohistochemically, the cells were positive for vimentin and SMA and negative for desmin, S100, and CD34. Based on these morphological and immunohistochemical features, a diagnosis of nodular fasciitis was made. We emphasize that nodular fasciitis of the breast may show clinical features and imaging findings similar to those of breast cancer. The histopathologic diagnosis of nodular fasciitis can also be challenging. The purpose of this case report is to highlight (...) The Rare Benign Lesion That Mimics a Malignant Tumor in Breast Parenchyma: Nodular Fasciitis of the Breast We herein report the clinical and pathological findings of a rare case of nodular fasciitis in the breast parenchyma of a 48-year-old female. Because of potentially malignant findings on ultrasonography and during clinical examination, the patient underwent an excisional biopsy. Histologically, the lesion was composed of spindle to round shaped cells arranged in short bundles

2018 Case Reports in Pathology

20. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer

on the stage of the disease at diagnosis, the treatment received and the biology of the tumour. More than 90% of women diagnosed with early breast cancer survive for at least 5 years, and 78% survive for 10 years (Cancer Research UK 2016). In contrast, only 13% of those diagnosed with advanced disease survive for more than 5 years. The diagnostics and care pathways Diagnosis Diagnosis 2.7 Breast cancer may be diagnosed following an abnormal result in the NHS breast cancer screening programme, or after (...) Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer T T umour profiling tests to guide adjuvant umour profiling tests to guide adjuvant chemother chemotherap apy decisions in early breast y decisions in early breast cancer cancer Diagnostics guidance Published: 19 December 2018 nice.org.uk/guidance/dg34 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our

2019 National Institute for Health and Clinical Excellence - Diagnostics Guidance

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>